We are entertaining the licencing discussions and due diligence by the pharmaceutical company which is very experienced in acromegaly....
There are not that many who are as this is a very specialised and confined market space with only 85k patients, his coughing and slight hesitation at this time during the speech clearly indicated that we are talking about Pfizer here.
Mark mentioned Pfizer repeatedly at other times, something which is not desired by a pharma if no link is apparent.
I do believe that ANP management is attempting to maintain independence, with it maximizing the positive effects for ANP and its shareholders for when deal is in place, in the progress of Pfizer moving aggressively forward to secure ATL1103 for a combined application for acromegaly in combination with existing Somavert treatments.
ta ... waiting for strength, page-6
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |